- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05361031
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center, Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females ≥ 19 years of age and ≤ 65 years of age
- Patients with confirmed diagnosis of CMT1A by genetic testing
- Patients with mild to moderate severity assessed by Charcot Marie Tooth Neuropathy Score version 2 (CMTNS v2) with a score > 2 and ≤ 20
- Individuals with lower limb muscle weakness with minimum dorsiflexion or more
- Individuals who voluntarily consented to participate in this study and signed the IRB approved informed consent form after listening to a description on the characteristics of this clinical study prior to all screening tests
- Individuals who can comply with the requirements in the clinical study
- In case of females of child bearing potential, those who test negative in a urine or serum pregnancy test at screening
- Individuals who practice medically approved contraceptive methods throughout the clinical study
Exclusion Criteria:
- Patients with significant respiratory, circulatory, renal, gastrointestinal, hepatic, endocrine, hematologic, psychiatric disorders or other severe diseases, or alcohol or drug addiction who may develop safety issues or cause confusion in the interpretation of the clinical study results as determined by the principal investigator
- Patients with other neuromuscular diseases or neuropathy-inducing factors: Patients with chronic alcohol addiction, undergoing anticancer chemotherapy, or taking neurotoxic drugs
- Patients diagnosed with diabetes
- Patients diagnosed with inflammatory bowel disease
- Patients with a history of stroke or cerebral ischemic attack within 12 months prior to the screening date
- Patients with a history of coronary artery disease, such as myocardial infarction and unstable angina pectoris, within 12 months prior to the screening date
- Morbidly obese patients with body mass index (BMI) ≥ 37
- Patients who underwent orthopedic surgery (corrective surgery for bone and ligament, artificial joint implantation, osteosynthesis, osteotomy, arthroscopic surgery) in the lower limbs within 6 months prior to the screening date
- Patients who may be affected by the muscle strength measurement test due to ankle contracture or surgery
- Patients with uncontrolled hypertension (if systolic blood pressure is ≥ 160 mmHg or diastolic blood pressure is ≥ 100 mmHg at screening)
- Patients or patient's immediate family members (parents, siblings, offspring) with a history of malignant tumors within the last 5 years prior to the screening date, excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin (if it is determined that there is no possibility of relapse after resection), or with a family history of familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC)
Patients who have not completed a national cancer screening program applicable to their sex and age (if it cannot be confirmed that the relevant test was received at a national cancer screening center or a recognized screening center)
However, if it is confirmed that the relevant test was received at a national cancer screening center or a recognized screening center during the screening period, and that the results were within normal range, the patients may participate in the clinical study.
Common to males and females: If a patient is ≥ 50 years of age, the results of a colonoscopy within 5 years prior to the screening must be determined as being within normal range, and if adenomatous polyps are evident, the results of a colonoscopy within 1 year must be determined as being within normal range (inflammatory polyps or hyperplastic polyps are included in the normal range). If a patient is ≥ 40 years of age, the results of a gastroscopy within 2 years prior to the screening must be within normal range. If a patient is ≥ 54 years of age and has a 30 pack-year history of smoking or more, the results of a low-dose chest CT within 2 years prior to the screening must be within normal range. In case of liver cancer, carriers of hepatitis B or hepatitis C virus and patients with hepatic cirrhosis fall under the exclusion criteria.
Females: For females ≥ 40 years of age, normal range findings must be confirmed in a mammogram within 2 years. For females ≥ 20 years of age, normal range findings must be confirmed in a Pap smear within 2 years.
- Patients diagnosed with active pulmonary tuberculosis
- Patients with HBV or HCV
- Patients who test positive in human immunodeficiency virus (HIV) antibody test
- Patients in an immunosuppressive state due to treatments such as immunosuppressants, chemotherapy, and radiotherapy
- Patients with a history of mental disease within 6 months prior to the screening date, which may interfere with participation in the study
- Patients who must take medications, that are known to have significant drug interactions within 14 days after the first administration of the investigational product or deemed unsuitable by the investigator's judgment
- Individuals who participated in another clinical study within 6 months before the time of screening
- Individuals who have shown significant adverse events such as hypersensitivity reactions to the investigational product
- Pregnant or breastfeeding females
- Other individuals determined ineligible by the principal investigator to participate in the clinical study due to other reasons including clinical laboratory test results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Engensis (VM202)
56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.
|
Intramuscular injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of intramuscular (IM) injections of Engensis in Participants
Time Frame: Day 0 visit to the Day 270 visit
|
Frequency and percentage of treatment-emergent adverse events (TEAEs) and serious adverse events after injections, injection site reactions, vital sign, and clinically significant laboratory values for Engensis.
|
Day 0 visit to the Day 270 visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Severity of disease changes following Engensis injections
Time Frame: Day 0, 90, 180 and Day 270]
|
As assessed using the CMTNS v2 (Charcot Marie Tooth Neuropathy Score version The scores range from 0-36.
The severity of disease shall be classified according to scores as mild (≤10), moderate (11 to 20), and severe (>20).
|
Day 0, 90, 180 and Day 270]
|
Evaluation of patient's neurological disability
Time Frame: Day 0, 90, 180 and Day 270
|
As assessed using the FDS (functional disability scale).
normal is 0 point, and if determined as bedridden, it is evaluated as 8 points.
|
Day 0, 90, 180 and Day 270
|
Evaluation of the activity level of patients with peripheral neuropathy
Time Frame: Day 0, 90, 180 and Day 270
|
As assessed using the overall neuropathy limitation scale (ONLS) leg scale.
It is scored from 0 to 7. The worst score, 7 points, is defined as restricted to wheelchair, or bed most of the day, unable to make any purposeful movements of the leg.
|
Day 0, 90, 180 and Day 270
|
Evaluation of patient's walking ability
Time Frame: Day 0, 90, 180 and Day 270
|
This test measures the time required for a subject to walk 10m through the 10-Meter Walking Test (10MWT) v2.2.
|
Day 0, 90, 180 and Day 270
|
Changes in fatty infiltration level of lower limb muscles
Time Frame: Day 0 and Day 270
|
Imaged via MRI.
|
Day 0 and Day 270
|
Evaluation of the presence of a disorder in a neurotransmission pathway.
Time Frame: Day 0 and Day 270
|
As assessed using the Nerve Conduction Study (NCS) v2.0
|
Day 0 and Day 270
|
Evaluation of the presence of hepatocyte growth factor in the body.
Time Frame: Day 0 and Day 270
|
As assessed using Anti-HGF Ab test
|
Day 0 and Day 270
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Stomatognathic Diseases
- Neurodegenerative Diseases
- Peripheral Nervous System Diseases
- Heredodegenerative Disorders, Nervous System
- Nervous System Malformations
- Polyneuropathies
- Tooth Diseases
- Nerve Compression Syndromes
- Charcot-Marie-Tooth Disease
- Hereditary Sensory and Motor Neuropathy
Other Study ID Numbers
- VMCMT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMT
-
i4HealthCompassionate Mind FoundationCompletedComparison of Internet-based CBT and CMTUnited States
-
University of South FloridaNational Institute of Neurological Disorders and Stroke (NINDS); University...CompletedCongenital Abnormalities | Genetic Diseases, Inborn | Nerve Compression Syndromes | Hereditary Sensory and Motor Neuropathy | Heredodegenerative Disorders, Nervous System | Tooth Diseases | Charcot Marie Tooth Disease (CMT)United States
-
The Third Xiangya Hospital of Central South UniversityNot yet recruitingCharcot-Marie-Tooth Disease (CMT)
-
University Medical Center GoettingenCompleted
-
St George's, University of LondonUniversity College London HospitalsUnknownPeripheral Neuropathy | CMT - Charcot-Marie-Tooth Disease | Hereditary Peripheral Neuropathy | CMT1AUnited Kingdom
-
University Hospital, Clermont-FerrandCompletedCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | CMT (Charcot Marie Tooth Disease)France
-
Children's Hospital of PhiladelphiaIllumina, Inc.Active, not recruitingMucopolysaccharidoses | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2 Gangliosidosis | Zellweger... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaEli Lilly and Company; University of Pennsylvania; Takeda; National Institute of... and other collaboratorsRecruitingMucopolysaccharidoses | Leukoencephalopathies | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2... and other conditionsUnited States
Clinical Trials on Engensis (VM202)
-
Helixmith Co., Ltd.TerminatedFoot Ulcer, DiabeticUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedPainful Diabetic NeuropathiesUnited States, Korea, Republic of
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.Completed
-
Helixmith Co., Ltd.CompletedAmyotrophic Lateral SclerosisUnited States, Korea, Republic of
-
Helixmith Co., Ltd.Completed
-
Helixmith Co., Ltd.Withdrawn
-
Helixmith Co., Ltd.CompletedAmyotrophic Lateral SclerosisUnited States
-
Helixmith Co., Ltd.RecruitingDiabetic Peripheral NeuropathyUnited States